Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  QJM : monthly journal of the Association of Physicians

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/qjmed/hcs173PMID 23019590
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis.

  2012cited by this paper
• A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis.

  2011cited by this paper
• British Thoracic Society guideline for non-CFbronchiectasis

  2010cited by this paper
• Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis

  2009cited by this paper
• A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis

  2009cited by this paper
• Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis.

  2007cited by this paper
• Characterisation of the onset and presenting clinical features of adult bronchiectasis.

  2006cited by this paper
• Rene Theophile Hyacinthe Laënnec (1781-1826): the man behind the stethoscope.

  2006cited by this paper
• Outcome in Adult Bronchiectasis

  2005cited by this paper
• Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)

  2003cited by this paper
• Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors

  2002cited by this paper
• Bronchial inflammation and colonization in patients with clinically stable bronchiectasis.

  2001cited by this paper
• How should health-related quality of life be assessed in patients with COPD?

  2000cited by this paper
• Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonasinfection of the lungs

  2000cited by this paper
• Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis.

  2000cited by this paper
• The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis.

  1998cited by this paper
• Patient-assessed health outcomes in chronic lung disease: what are they, how do they help us, and where do we go from here?

  1997cited by this paper
• Effect of sputum bacteriology on the quality of life of patients with bronchiectasis.

  1997cited by this paper
• Validation of the St. George's Respiratory Questionnaire in bronchiectasis.

  1997cited by this paper
• Improved survival in the Danish center‐treated cystic fibrosis patients: Results of aggressive treatment

  1996cited by this paper
• Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa.

  1996cited by this paper
• Guidelines for the measurement of respiratory function

  1994cited by this paper
• Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists.

  1994cited by this paper
• The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.

  1992cited by this paper
• Development of a shuttle walking test of disability in patients with chronic airways obstruction.

  1992cited by this paper
• A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

  1992cited by this paper
• Elastolytic activity of sputum and its relation to purulence and to lung function in patients with bronchiectasis.

  1984cited by this paper

• Management erwachsener Patientinnen und Patienten mit Bronchiektasen-Erkrankung

  2024cites this paper
• The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol

  2022cites this paper
• Antibiotic Management in Bronchiectasis.

  2022cites this paper
• Is out‐patient based treatment of bronchiectasis exacerbations in children comparable to inpatient based treatment?

  2020cites this paper
• Pediatric Pulmonology

  2020cites this paper
• Epidemiología y diversidad geográfica de las bronquiectasias

  2020cites this paper
• Contemporary Concise Review 2018: Bronchiectasis

  2019cites this paper
• British Thoracic Society Guideline for bronchiectasis in adults

  2018cites this paper
• Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis

  2018cites this paper
• Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis

  2018cites this paper
• Pseudomonas aeruginosa and Bronchiectasis

  2018cites this paper
• ‘Good enough’ is ‘not enough’ when managing indigenous adults with bronchiectasis in Australia and New Zealand

  2018cites this paper
• The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis

  2017cites this paper
• 【投稿】気管支拡張症revisited－今，欧米を中心に研究の大きなうねり 第2部：診断，治療

  2017cites this paper
• Cough and bronchiectasis.

  2017cites this paper
• New therapies for the prevention and treatment of exacerbations of bronchiectasis

  2017cites this paper
• Annual direct medical costs of bronchiectasis treatment

  2016cites this paper
• epidemiología actual y costes de las bronquiectasias

  2016cites this paper
• Long-term antibiotic treatment for non-cystic fibrosis bronchiectasis in adults: evidence, current practice and future use

  2016influential citation
• Emerging drugs for bronchiectasis: an update

  2015cites this paper
• Developing drug therapies in bronchiectasis

  2015cites this paper
• Bronchiectasis: which antibiotics to use and when?

  2015cites this paper
• New therapeutic options for noncystic fibrosis bronchiectasis.

  2015cites this paper
• KEY POINTS Chronic low-dose macrolide therapy in patients with NCFB has resulted in improved quality of life and a decreased exacerbation rate in several randomized controlled trials

  2015cites this paper
• Bronchiectasis: an update on current pharmacotherapy and future perspectives

  2014cites this paper
• The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: A case–control analysis

  2014cites this paper
• Defining severity in non-cystic fibrosis bronchiectasis

  2014cites this paper
• Bronchiectasis: still a problem

  2014cites this paper
• Antimicrobial treatment of non-cystic fibrosis bronchiectasis

  2014cites this paper
• Elements: in this month's issue.

  2014cites this paper
• Management of non-cystic fibrosis bronchiectasis

  2013cites this paper
• Pyocyanique et bronchectasies mucoviscidosiques et non mucoviscidosiques de l’adulte : de la colonisation à l’infection

  2013cites this paper
• Emerging drugs for bronchiectasis

  2012cites this paper